08.00 · Coffee and Registration
08.30 · Chairman's Opening Remarks
Dr. Willem Schoonen
Group Leader In Vitro Toxicology and Toxicogenomics
NV Organon, Schering-Plough Corporation
08.45 · Improved Risk Assessment Due to Challenges by 3R’s Principal
Dr.Rita Cortvrindt
CEO
Eggcentris NV
09.30 · Predictive In Vivo Toxicity and Safety Screening in the Zebra fish
Dr. Adrian Hill
Head of Toxicology
Summit plc
10.15 · Networking Coffee Break
10.45 · Mechanisms of Toxicity and In Vitro Methods to Determine Toxic Potential and Their Use by Pharmaceutical Companies for Drug Development
Dr. Nicky Hewitt
European Scientific Consultant
SWS/DMPKORE
11.30 · High Throughput Screening for In Vitro Toxicity Screening: A Gradual Acceptance of New Test Methods
Dr. Willem Schoonen
Group Leader In Vitro Toxicology and Toxicogenomics
NV Organon, Schering-Plough Corporation
12.15 · Networking Lunch
13.45 · Early Toxicity Screening Strategy at UCB-Pharma
Dr. Franck Atienzar
Head In Vitro Toxicology Unit
UCB-Pharma
14.30 · A Strategy in Genotoxicity Testing for Drug Development: Some Examples
Dr. Elisabeth Lorge
Head of Genetic Toxicology Unit
Servier Group
15.15 · The Importance of the In Vivo Comet Assay in Genotoxicity Testing
Dr. Hajime Kojima
Director of JaCVAM
Division of Pharmacology, Biological Safety Research Center
National Institute of Health Sciences, Japan
16.00 · Networking Coffee Break
16.30 · HERG-450: Combining Assays for Safety Assessment of Drug Candidates
Dr. Katya Tsaioun
CEO
Apredica
17.15 · Using Allele-specific Competitive Blocker PCR Measurement of
Tumor-Associated Mutations to Predict Carcinogenesis
Dr. Barbara Parsons
Research Microbiologist
Division of Genetic and Reproductive Toxicology
National Center for Toxicological Research (US FDA)
18.00 · Chair's Closing Remarks
18.30 · End of Day One
08.00 · Coffee and Registration
08.30 · Chairman's Opening Remarks
Dr James McKim
President and CEO
CeeTox
08.45 · A Novel In Vitro Model for Blood-to-Brain Absorption
Dr. Hinnerk Boriss
CEO
Nimbus-Biotech/Sovicell
09.30 · Interpreting Compound Profiles in the Context of the Human Drug Experience
Dr. Jacques Migeon
Principal Scientist
Cerep Inc
10.15 · Networking Coffee Break
10.45 · Human Microdosing, Growing Acceptance and Implementation of Phase 0 Studies and What Impact the CREAM Trial Results Will Have on the Industry
Dr. Mark Seymour
Chief Study Director
Xceleron Ltd.
11.30 · Time-Dependent CYP Inhibition
Dr. Ken Grime
Team Leader Discovery DMPK
Astra-Zeneca
12.15 · Networking Lunch
13.45 · Mechanism-Based Inactivation of Human Cytochrome P450 Enzymes: Strategies for Diagnosis and Drug-Drug Interaction Risk Assessment
Dr. Amin Rostami
Professor of Systems Pharmacology
University of Sheffield
Director of Scientific Development
Simcyp Limited
14.30 · Translational In Vitro Toxicology: Collecting and Interpreting In Vitro Toxicity Data that has In Vivo Relevance
Dr. James McKim
President & CEO
CeeTox, Inc
15.15 · Comprehensive Reversible QSAR in Toxicity and Biological Activity: Fragment Approach
Dr. Tarmo Tamm
Head Research and Development
Molcode Ltd.
16.00 · Networking Coffee Break
16.30 · ADME/DMPK Optimisation Strategies and Unpredictable Toxicity: Room for Thought?
Dr. Constance Höffer
Founder and CSO
DMPKORE
17.15 · Predictive Toxicology in Europe - an Integrated Project within the "Innovative Medicines for Europe" Initiative
Dr. Phil Hewitt
Head of Toxicogenomics
Merck Serono Research
18.00 · Closing Comments from the Chair
18.30 · Close Conference